Showing 5801-5810 of 7115 results for "".
- US FDA Approves Saphnelo for Lupushttps://practicaldermatology.com/news/us-fda-approves-saphnelo-for-lupus/2460876/The U.S. Food and Drug Administration (FDA) approved Saphnelo (anifrolumab-fnia) as a treatment for adults with systemic lupus erythematosus (SLE) who are receiving standard therapy. Developed by AstraZeneca, Saphnelo is a monoclonal antibody administered by intravenous (IV)
- FDA Approves of Sol Gel's Twyneo for Acnehttps://practicaldermatology.com/news/fda-approves-of-sol-gels-twyneo-for-acne/2460874/The FDA has approved Sol Ge's first proprietary drug product, TWYNEO (tretinoin/benzoyl peroxide) cream, 0.1%/3%, for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older. TWYNEO uses Sol-Gel’s patented technology to entrap tretinoin, a retinoid, a
- Allergan Aesthetics Continues Partnership with Girls Inc.https://practicaldermatology.com/news/allergan-aesthetics-continues-partnership-with-girls-inc/2460869/Allergan Aesthetics is starting its third consecutive year of partnership with Girls Inc. and debuting Empowering Confidence Workshops, a nationwide mentoring initiative. Based on a 2020 Girls Inc. report, many girls have a hard time picturing themselves in science, technology, eng
- LiVDerm Brings SBS Part II to Hollywood, FL this Fallhttps://practicaldermatology.com/news/livderm-brings-sbs-part-ii-to-hollywood-fl-this-fall/2460868/SBS Part II: The Aesthetic Dermatology Summit comes to Hollywood, FL, September 23-25, closing out the two-part 19th Annual South Beach Symposium. Produced by LiVDerm, the event is centered on the latest and most re
- Hoth Therapeutics, Inc.’s BioLexa in AD: So Far, So Safehttps://practicaldermatology.com/news/hoth-therapeutics-incs-biolexa-in-ad-so-far-so-safe/2460853/Hoth Therapeutics, Inc.’s BioLexa was well tolerated with no serious adverse events and no drug-related treatment-emergent adverse events observed, according to the safety results in Cohort 1 of its first in human clinical trial of the BioLexa platform to treat atopic dermatitis.
- Golden State Dermatology Adds Concord Practicehttps://practicaldermatology.com/news/golden-state-dermatology-adds-concord-practice/2460850/Curtis A. Raskin, MD, PhD, FAAD and his team are now part of Golden State Dermatology. The clinic in Downtown Concord adds to the eight new locations Golden State added in 2020, after adding eight in 2019. Dr. Raskin received his medical degree and PhD in molecular biology from State Un
- Study: Skin Reactions After COVID-19 Vaccines Are Rarehttps://practicaldermatology.com/news/study-skin-reactions-after-covid-19-vaccines-are-rare/2460848/Skin problems such as itchiness, rashes, hives and swelling can occur in some individuals after receiving a COVID-19 vaccine, but new research suggests that these reactions are rare, and that even when they do occur with an initial COVID-19 vaccination, they seldom recur after receiving a second
- OMNY Health Launches Integrated Dermatology Data Repository and Research Networkhttps://practicaldermatology.com/news/omny-health-launches-integrated-dermatology-data-repository-and-research-network/2460845/OMNY Health has partnered with community-based dermatology practices to create a first-of-a-kind integrated, normalized, de-identified electronic health record (EHR) data repository for dermatological research. The assembled longitudinal data represents care delivered over the pas
- Nutrafol Launches Postpartum Formulahttps://practicaldermatology.com/news/nutrafol-launches-postpartum-formula/2460838/The first-of-its-kind postpartum hair nutraceutical is now available from Nutrafol. Nutrafol Postpartum was developed with an OB/GYN to target the root causes of excess hair shedding and thinning post-pregnancy. It is intended to help the body recover from the physical stress of childbirth,
- AAD Survey: Only a Third of Americans are Concerned about Skin Cancer Despite Nearly 70% Having at Least One Risk Factorhttps://practicaldermatology.com/news/aad-survey-only-a-third-of-americans-are-concerned-about-skin-cancer-despite-nearly-70-having-at-least-one-risk-factor/2460836/Despite skin cancer being the most common cancer in the U.S., only about one-third of adults are concerned about developing the disease, even though nearly 70 percent say they have at least one risk factor for skin cancer, according to a new American Academy of Dermatology (AAD) survey.